Clinically Silent Corticotroph Tumors of the Pituitary Gland
- 1 September 2000
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurosurgery
- Vol. 47 (3), 723-730
- https://doi.org/10.1097/00006123-200009000-00039
Abstract
OBJECTIVE: To determine the clinical presentation, imaging characteristics, microscopic and ultrastructural characteristics, and treatment outcomes of patients with clinically silent pituitary corticotroph adenomas. METHODS: All silent corticotroph adenomas diagnosed at the Mayo Clinic during the years 1975 through 1997 were selected from the files of the Mayo Tissue Registry. RESULTS: We studied 23 cases, occurring in 16 male and 7 female patients (age range, 11–79 yr; mean age, 48 yr), who presented with headaches (50%), visual field defects (61%), extraocular muscle paresis (13%), hypopituitarism (26%), and galactorrhea/amenorrhea (43%/29% of the female patients). No patients exhibited clinical hypercortisolism. All tumors were macroadenomas (2.4 ± 0.8 cm; range, 1.5–4.0 cm) and exhibited suprasellar extension in 87% of the cases and hemorrhage, necrosis, and/or cystic changes in 61%. All tumors stained were variably periodic acid-Schiff-, adrenocorticotropic hormone-, and β-endorphin-positive, particularly Subtype I lesions. Ultrastructural classification was performed in 19 cases. In a comparison of Subtype I and II tumors, differences were observed with respect to sex (male/female, 1.4:1 versus 6:1), preoperative hyperprolactinemia (5 of 16 versus 0 of 6 cases), preoperative hypopituitarism (9 of 16 versus 5 of 7 cases), radiographic or gross invasion (7 of 16 versus 5 of 7 cases), and partial or total postoperative pituitary failure (6 of 16 versus 6 of 6 cases). The overall median postoperative follow-up period was 4.9 years (range, 0.3–16.6 yr); 54% of the patients had persistent or recurrent tumors. CONCLUSION: Clinically silent corticotroph adenomas behave in an aggressive manner and are characterized by the following: lack of clinical signs or symptoms of Cushing's syndrome and normal cortisol levels; no or only minor elevations of serum adrenocorticotropic hormone levels; macroadenomas with hemorrhagic infarction; and presentation dominated by mass effect symptoms. The high persistence/recurrence rate underscores the need for long-term follow-up.Keywords
This publication has 12 references indexed in Scilit:
- Pars intermedia of the human pituitary revisited: Morphologic aspects and frequency of hyperplasia of POMC-peptide immunoreactive cellsEndocrine Pathology, 1999
- Silent Corticotroph Adenoma: Case Report and Literature ReviewEndocrine Practice, 1997
- Pituitary carcinomaCancer, 1997
- A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27Kip1-Deficient MiceCell, 1996
- Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27Cell, 1996
- Mice Lacking p27 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary TumorsCell, 1996
- Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and Cushing's diseaseJournal of Neurosurgery, 1990
- A Novel Type of Pituitary Adenoma: Morphological Features and Clinical CorrelationsJournal of Clinical Endocrinology & Metabolism, 1988
- A Pituitary Adenoma Secreting High Molecular Weight Adrenocorticotropin without Evidence of Cushing’s DiseaseJournal of Clinical Endocrinology & Metabolism, 1987
- Proopiolipomelanocortin Peptides in Normal Pituitary, Pituitary Tumor, and Plasma of Normal and Cushing's Horses*Endocrinology, 1982